ProPhase Labs, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ProPhase Labs, Inc. stock issued during period, value, stock options exercised for the quarter ending 2018-12-31 was $0.00.
- ProPhase Labs, Inc. stock issued during period, value, stock options exercised for the quarter ending 2018-09-30 was $0.00.
- ProPhase Labs, Inc. stock issued during period, value, stock options exercised for the quarter ending 2013-12-31 was $0.00.
- ProPhase Labs, Inc. stock issued during period, value, stock options exercised for fiscal 2018 was $338.00K, a 77.62% decline from fiscal 2017.
- ProPhase Labs, Inc. stock issued during period, value, stock options exercised for fiscal 2017 was $1.51M.
- ProPhase Labs, Inc. stock issued during period, value, stock options exercised for fiscal 2013 was $27.00K.
- ProPhase Labs, Inc. stock issued during period, value, stock options exercised for fiscal 2010 was $133.00K, a 4.72% increase from fiscal 2009.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $338.00K 10-K · filed 2019-03-26 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | |
| 2017-12-31 | $1.51M 10-K · filed 2019-03-26 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | $27.00K 10-K · filed 2016-03-29 |
| 2010-12-31 | $133.00K 10-K · filed 2013-03-28 | |
| 2009-12-31 | $127.00K 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |